阿尔茨海默病临床试验大会（The Clinical Trials on Alzheimer's Disease conference, CTAD）是一个专注于阿尔茨海默病治疗及临床试验相关的国际大会，来自行业内和学术界的阿尔茨海默病研究领域领军人物和专业人士，一年一度汇聚一堂，建立合作伙伴关系，推动有效的治疗手段、加速先进药物的研发、对抗疾病的发生和蔓延，以造福患者为目标，而齐心协力共同努力。

The Clinical Trials on Alzheimer's Disease conference (CTAD) is an international conference focused on treatment and clinical trials related to Alzheimer's disease. Each year, leading figures and professionals from both industry and academia in the field of Alzheimer's research come together to establish partnerships, promote effective treatment methods, accelerate the development of innovative drugs, and address the onset and spread of the disease, all with the ultimate goal of benefiting patients.

2024 年 10 月 29 日-11 月 1 日 CTAD 于西班牙马德里市举办一年一度的阿尔茨海默病临床试验大会(CTAD2024)，内容涵盖阿尔茨海默病领域最新研究进展及热点问题。为加强我国阿尔茨海默病领域与国际学术界的交流与合作，Wiley 作为阿尔茨海默病临床试验大会（CTAD）在中国的唯一授权合作方，由礼来中国提供学术支持，计划在中国举办“Best of CTAD 2024 in China”系列学术专场。会议邀请到 CTAD2024 大会上的学术专家与国内顶尖阿尔茨海默病专家共同交流并探讨阿尔茨海默病临床及学术上的热点问题，激扬思想，共促领域新未来。

From October 29 to November 1, 2024, CTAD held its annual conference in Madrid, Spain, covering the latest research advances and hot topics in the field of Alzheimer's disease. To strengthen communication and collaboration between China's Alzheimer's disease sector and the international academic community, Wiley, as the exclusive authorized partner of the Clinical Trials on Alzheimer's Disease (CTAD) conference in China, with academic support from Eli Lilly China, is hosting the "Best of CTAD 2024 in China" series of academic webinars. The event will bring together academic experts from CTAD 2024 and top Alzheimer's disease specialists in China to discuss critical issues in both clinical and academic aspects of Alzheimer's disease, promoting the exchange of ideas and paving the way for a brighter future in the field.